| Acer Therapeutics is a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with unmet medical need. Co.'s pipeline includes three clinical-stage candidates: EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001 (a fully taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders and Maple Syrup Urine Disease; and osanetant for the treatment of various neuroendocrine disorders. We show 9 historical shares outstanding datapoints in our ACER shares outstanding history coverage, used to compute ACER market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ACER market cap history over the course of time is important for investors
interested in comparing ACER's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ACER versus a peer is one thing; comparing
ACER market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ACER can fluctuate over the course of history.
With this page we aim to empower investors researching ACER by allowing them to research the ACER market cap history.